We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Bioinvent International Ab | LSE:0H22 | London | Ordinary Share | SE0015244520 | BIOINVENT INTERNATIONAL ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 18.10 | 17.20 | 19.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
LUND, Sweden, May 22, 2019 /PRNewswire/ --
Important events in the first quarter and after the reporting period
Comments from the CEO
Martin Welschof, CEO of BioInvent, comments: "BioInvent continued to make good progress in the first quarter, advancing our pipeline and further validating our unique F.I.R.S.TTM platform allowing us to yield actionable leads and develop therapies which have the potential to make a significant difference in the lives of cancer patients. We are progressing BI-1206, our lead antibody, for treatment of a range of hematological cancers and are aiming to add three clinical programs in solid cancer.
Our comprehensive program to target TNFR2 for cancer therapy shows the potential in the n-CoDeR® and F.I.R.S.TTM platforms, which have generated a broad panel of highly specific anti-TNFR2 antibodies, including our lead candidate antibody BI-1808. The milestone payment received from Mitsubishi related to the initiation of a Phase II trial further validates the platform, and we are pleased to have extended the platform's patent protection in the United States.
We also extended our collaboration with Transgene to develop multifunctional oncolytic viruses for the treatment of solid tumors, which further confirms our positive working relationship.
In the near term, we are looking forward to several important milestones, which include the initiation of clinical development of our second anti-FcγRIIB program in combination with an anti-PD1 antibody; the presentation of a BI-1206/rituximab abstract at an international lymphoma conference; and the results from a Phase II study evaluating THR-317 in combination with ranibizumab, expected in Q3 2019.
Based on these clinical advances, we remain focussed on opportunities to partner our product candidates. We will consider carefully how best to use our financing to ensure we prioritize the most promising opportunities to deliver solutions for patients and value for our shareholders."
Contact
Any questions regarding this report will be answered by Martin Welschof, CEO, +46(0)46-286-85-50, martin.welschof@bioinvent.com. The report is also available at http://www.bioinvent.com/.
BioInvent International AB (publ)
Co. reg. no. 556537-7263
Address: Sölvegatan 41, 223 70 Lund
Tel.: +46(0)46-286-85-50
info@bioinvent.com
Forward looking information
This interim report contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual out-come may deviate significantly from the scenarios described in this press release.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
https://mb.cision.com/Main/583/2822144/1049756.pdf | BioInvent Interim Report January 1 â€" March 31 2019 (PDF) |
View original content:http://www.prnewswire.com/news-releases/bioinvent-interim-report-january-1--march-31-2019-300854853.html
SOURCE BioInvent
Copyright 2019 PR Newswire
1 Year Bioinvent International Ab Chart |
1 Month Bioinvent International Ab Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions